Fundraising FoxMotley Bio
AntlerPlug and Play VenturesSilicon Valley, US · 2 known investors
Find your way into Motley Bio
Sign up to see every warm intro you have to Motley Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Motley Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Motley Bio is a Silicon Valley company applying multiomics analysis to the study of disease at early stages. Its work is directed at identifying the biological changes that precede clinical symptoms, for use in research and diagnostics.
Also known as Motley Bio
Investors · 2
How we know: open dataset · Top 3000 Accelerator Startups (no YC) 2026-08 · Not right? Tell us
How we know: open dataset · Top 3000 Accelerator Startups (no YC) 2026-08 · plugandplaytechcenter.com · Not right? Tell us
Company profile
researched Sep 2026Motley Bio is a California-based biotechnology company built around a proprietary multi-omic sequencing technology that profiles DNA, RNA and proteins simultaneously using a single assay that produces a single readout. The company positions this capability for drug discovery, biomarker identification and early cancer detection, serving biotech and pharmaceutical customers.
Alongside its sequencing technology, the company offers multi-omics data analysis services covering integration of multiple omics modalities, statistical analysis and visual reporting in support of disease-biology research. Stated expertise areas include multi-omics integration, disease-focused molecular research, bioinformatics and computational analysis, biomarker discovery, and omics data visualization and interpretation. Listed key technologies include bioinformatics pipelines, high-throughput sequencing data analysis, proteomics and metabolomics data analysis, and statistical modeling for omics.
Business model
The company combines a proprietary sequencing assay with analytical and interpretation services delivered to biotech and pharmaceutical organizations conducting drug discovery, biomarker and early-detection research.
Traction
Selected into the Creative Destruction Lab CDL-Global Cancer stream for the 2024/25 cohort year; listed as a member organization in MTEC's life-sciences directory. Company size is reported as 1-50 employees.
▸Full profile — market position, technology, go-to-market, geography
Market position
An early-stage biotechnology company in the multi-omics and early cancer detection segment, present in the Creative Destruction Lab cancer stream cohort and in the MTEC life-sciences member directory.
Motley Bio describes its single-assay, single-readout approach as producing richer and more comprehensive data at lower cost and with lower internal data variability than running multiple individual assays, with higher reported sensitivity and specificity for mutation detection and the ability to work from small patient sample volumes.
Technology
A proprietary multi-omic sequencing assay measures DNA, RNA and proteins in one experiment producing one readout, in place of multiple separate assays. The company states the approach yields lower internal data variability, higher sensitivity and specificity for mutation detection than competing methods, and can generate multi-omic data from small quantities of patient sample. Supporting capabilities include bioinformatics pipelines, high-throughput sequencing data analysis, proteomics and metabolomics analysis, and statistical modeling for omics data.
Go-to-market
Biotech and pharmaceutical companies pursuing drug discovery, biomarker identification and early cancer detection, as well as research groups requiring multi-omics data analysis.
Geography
Headquartered in California, United States, with a location listed in San Mateo, California.
Compiled by commissioned research from 5 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsMotley Bio participated in the Creative Destruction Lab CDL-Global site, Cancer stream, cohort year 2024/25.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 5
primary sources listed
- Motley Bio - Creative Destruction Labcreativedestructionlab.com · web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Motley Bio do?
- Motley Bio develops multi-omic sequencing that profiles DNA, RNA and proteins in a single assay for disease research.
- Who are Motley Bio's investors?
- Motley Bio's investors include Antler, Plug and Play Ventures.
- Where is Motley Bio headquartered?
- Motley Bio is headquartered in Silicon Valley, US.